Solubilization of the opiate receptor

The opiate receptor is solubilized from rat neural membranes by treating the membranes with Triton X-100, followed by centrifugation. Removal of the Triton X-100 was accomplished with Bio-beads SM-2, and the resulting supernatant was capable of stereospecifically binding opiates at 10^?13 moles/mg protein under saturating conditions. Stereospecific binding was measured by equilibrium dialysis and gel filtration using a Sephadex G-25 column, equilibrated with [³H] -ligand and either dextrorphan or levorphanol. The solubilized receptor has affinities for the opiates similar to those observed in membrane preparations and $\text{in vivo}$ experiments. The addition of phosphatidylserine to the supernatant enhances stereospecific binding of etorphine slightly. Phospholipase A₂, trypsin and chymotrypsin completely inhibit binding. The addition of albumin prevents, but does not reverse the inhibition caused by low concentrations of phospholipase A₂. Phosphatidylserine decarboxylase inhibits stereospecific binding by 95%, despite the fact only 10% of the phosphatidylserine present in the supernatant is converted to phosphatidylethanolamine. The solubilized opiate receptor, like the receptor in neural membranes, appears to consist of both protein and lipid moieties.     

An intracellular opiate receptor

The adrenal medulla contains an intracellular opiate receptor associated with the chromaffin granule. This receptor may participate in regulation of the catecholamine content of the granule.     

Autoradiograhic localization of the opiate receptor in rat brain.

One hour after injection of the potent opiate antagonist ³H-diprenorphine (125 μCi, 13 Ci/mmole) 75–85% of the drug is associated with opiate receptor sites. Autoradiography of fresh frozen unfixed brain has been carried out to visualize receptor distribution. Dense clusters of autoradiographic grains are highly localized in the caudate-putamen, locus coeruleus, zona compacta of the substantia nigra and the substantia gelatinosa.     

Identification of opiate receptor binding in intact animals.

After intravenous administration of ³H-naloxone to rats, particulate bound radioactivity accumulated in the brain is selectively associated with opiate receptor binding sites, providing a means of labeling the opiate receptor $\text{in vivo}$. The regional distribution of ³H-naloxone bound $\text{in vivo}$ closely parallels regional differences in opiate receptor binding $\text{in vitro}$ with highest levels in the corpus striatum, negligible receptor-associated binding in the cerebellum and intermediate levels in other regions. ³H-Naloxone binding $\text{in vivo}$ is saturable with the same total number of binding sites determined $\text{in vivo}$ as by $\text{in vitro}$ procedures. Nalorphine is markedly more potent than morphine in inhibiting ³H-naloxone binding $\text{in vivo}$ and non-opiates are ineffective. The half-life for dissociation of ³H-naloxone bound to particles $\text{in vivo}$ is the same as its dissociation rate after binding occurs $\text{in vitro}$, and sodium stabilizes ³H-naloxone bound $\text{in vivo}$ from initial rapid dissociation as predicted from the known properties of the opiate receptor $\text{in vitro}$.     

An opiate receptor on frog sciatic nerve axons.

The effect of meperidine (3 X 10(4) M) on the action potential of frog sciatic nerve was examined by means of the double sucrose gap technique. Meperidine decreased the amplitude, maximum rate of depolarization, and maximum rate of repolarization of the action potential but had no effect on the resting potential. This depression in amplitude and maximum rate of rise was partially blocked by naloxone (1 X 10(-8) M) while the maximum rate of depolarization was further depressed. The data suggest that the effect of meperidine is due to two mechanisms, a nonspecific local anaesthetic like effect and an opiate receptor mediated effect.     

A protein-lipid model of the opiate receptor

The complexity of the opiate analgesia receptor is indicated by several lines of evidence which are reviewed in this paper: (1) heterogeneity of opiate-receptor interactions; (2) the effect of various enzymatic and chemical treatments of brain membranes on opiate binding; and (3) physico-chemical properties of detergent-extracted membrane components. Based on these findings, a model of the opiate-receptor is proposed which consists of both protein and lipid; the former contains a binding site for enkephalins, and the latter a site for alkaloids, with β-endorphin interacting with both sites. Some implications of this model are briefly discussed.     

Immunoaffinity-purified opiate receptor specifically binds the delta-class opiate receptor ligand, cis-(+)-3-methylfentanylisothiocyanate, SUPERFIT

Using an antibody generated against the opiate receptor on NG108-15 cells, we recently purified the putative receptor from this hybrid cell line. We herein report that the purified receptor complex specifically binds tritiated cis-(+)-3-methylfentanylisothiocyanate (SUPERFIT), with the predominant binding associated with a 58 kDa polypeptide chain. Consistent with these findings is the in situ labeling of a 58 kDa protein with [3H]SUPERFIT on NG108-15 cells.     

Monoclonal antibody to enkephalins with binding characteristics similar to opiate receptor

Monoclonal antibodies to enkephalins were established by immunization of mice with met-enkephalin, leu-enkephalin or both. Twenty-three clones with a high titer were classified into 6 types according to the binding properties to enkephalins and their derivatives. Antibody LM 239 showed binding characteristics similar to opiate receptor. It has a very high affinity to enkephalins and their derivatives which have a potent opioid activity, but a low affinity to enkephalin derivatives which devoid of opioid activity. The binding of 3H-met-enkephalin to the antibody was inhibited by naloxone and morphine, although the ID50 values were considerably higher than the Ka values of the alkaloids to opiate receptor.     

Possible involvement of cerebroside sulfate in opiate receptor binding.

Cerebroside sulfate (CS) appears to fulfill most of the structural requirements of a hypothetical opiate receptor. It possesses many of the properties that are thought to be necessary for the identification of an "opiate receptor," exhibiting high affinity and stereoselective binding to a number of narcotic drugs. Although these properties are insufficient to establish identity of the receptor, it is highly significant that the affinity of this binding can be correlated with the analgetic potency of these drugs in both man and rodents. CS is an endogenous component of brain tissue, and a partially purified opiate receptor from mouse brain has been found to be CS. Other experiments indicate that reduced availability of brain CS decreases the analgetic effects of morphine and this is accompanied by a reduction in number of binding sites, suggesting that the interaction of opiates with CS observed in vitro may also have importance in vivo. CS was also found to be a component of the opiate receptor after marking with 125I-labeled diazosulfanilic acid. The possibility that CS or the SO4-2 group of this lipid may be the "anionic site" of the opiate receptor should be considered.     

The interaction of ketamine with the opiate receptor

The analgesic effect of the anesthetic agent ketamine HCl is inhibited in rats by the narcotic receptor antagonist naloxone. Racemic (±) ketamine HCl also displaced ³H-naloxone in an opiate receptor binding-assay. The potency of ketamine in the assay was reduced nearly six-fold by sodium suggesting that the drug interacts as an agonist. However, some activity as an antagonist was not ruled out. The interaction of ketamine HCl with the opiate receptor was stereospecific with the (+) salt being more effective than the (-) salt. The stereoselective nature of the interaction is consistent with other studies (1) demonstrating that (+) ketamine HCl has a greater analgesic effect than the (-) salt.     

Differing stereospecificities distinguish opiate receptor subtypes

Paired stereoisomers of compounds active at the proposed mu, kappa and sigma classes of opiate receptors display differing stereoselectivity patterns at the receptor subtypes. The (-) isomers of cyclazocine and SKF-10047 are far more potent than the (+) isomers as displacers of [3H]dihydromorphine from receptors. However, the (-) isomers are only moderately more potent than the (+) isomers at displacing [3H]ethylketocyclazocine from kappa receptors in an assay controlled for radioligand binding to mu receptors, and the (+) and (-) isomers are similar in potency for displacement of [3H]phencyclidine (PCP) from sigma receptors. At the sigma/PCP receptor, (+) ketamine proved four times as potent as (-) ketamine, while the dioxalan derivative dexoxadrol is far more potent than its nearly inactive enantiomer levoxadrol. The results for the sigma/PCP receptor are in agreement with those of behavioral studies. Stereospecificity patterns may provide support for the concept of the opiate receptor subclasses as biochemically distinct entities.     

Discrimination by temperature of opiate agonist and antagonist receptor binding.

Variations in incubation temperature can markedly differentiate opiate receptor binding of agonists and antagonists. In the presence of sodium increasing incubation temperatures from 0° to 30° reduces receptor binding of ³H-naloxone by 50% while tripling the binding of the agonist ³H-dihydromorphine. Lowering incubation temperature from 25° to 0° reduces the potency of morphine in inhibiting ³H-naloxone binding by 9-fold while not affecting the potency of the antagonist nalorphine. At temperatures of 25° and higher the number of binding sites for opiate antagonists is increased by sodium and the number of sites for agonists is decreased by sodium with no changes in affinity. By contrast, in the presence of sodium lowering of incubation temperature to 0° increases opiate receptor binding of the antagonist naloxone by enhancing its affinity for binding sites even though the total number of binding sites are not changed.     

Lack of opiate receptor involvement in centrally induced calcitonin analgesia.

Calcitonin (CT) injected into the brain ventricles (ICV) of conscious rabbits induced an analgesia not reversable by naloxone which could be repeatedly elicited (for 5 days), while tolerance to morphine developed. CT and morphine synergized $\text{in vivo}$ when administered ICV in combination. CT did not alter electrically-induced contractions of guinea-pig myenteric plexus-longitudinal muscle and no displace of ³H-dihydromorphine by CT was observed in brain opiate receptor preparations. We have concluded that the mechanism of centrally induced CT analgesia may be opiate-independent.     

A potent peptide affinity reagent for the opiate receptor

The synthesis and characterization of a novel enkephalin analogue, Tyr-D-Ala-Gly-Phe-Leu-chloromethyl ketone, is described. The biological potency of the compound in various assays has been determined to be very high. The compound is an alkylating affinity reagent and irreversibly inactivates a defined population of enkephalin receptors in rat brain membrane preparations, as well as irreversibly inhibiting electrically stimulated contractions in the mouse vas deferens tissue preparation.     

Studies on brain opiate receptor stability in vitro: inhibition of opiate receptor binding by adenosine-5'-diphosphate

Incubation of rat brain homogenates at 37° causes a time-dependent decrease in opiate receptor binding which does not occur with a washed membrane fraction. The supernatant fraction contains a heat-stable inhibitor which is partially destroyed by apyrase and completely removed by activated charcoal. ADP causes a similar inhibitory effect in homogenates, but not with washed membranes, which is characterized by a decrease in both opiate agonist and antagonist binding in the absence or presence of NaCl. The ADP inhibition is antagonized by ATP, α,β-methyleneADP, β-thioADP and EDTA. It is concluded that ADP, unlike the guanine nucleotides, facilitates the nonspecific degradation of opiate receptors by an endogenous soluble factor.